Business
FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology
HOUSTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents
About this update from Fibrobiologics, Inc.
[{"type":"text","content":"HOUSTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent Office covering the use of fibroblast cell-based technology in an adhesive bandage for wound healing. “Our ongoing exploration of therapeutic applications using fibroblast cells continues to provide unique opportunities for our wound care platform,” commented Founder & CEO of FibroBiologics, Pete O’Heeron. “This patent, if issued, will allow us to pursue development of a room-temperature, shelf stable bandage that could be used in the post-surgical and retail setting.” “We believe that leveraging the unique healing capabilities of fibroblasts has the potential to transform wound care as we know it,” added Chief Scientific Officer of FibroBiologics, Hamid Khoja, Ph.D. “Combining the healing properties of fibroblasts with a stable, long-term delivery system could allow us to make advanced treatments more accessible to a wider audience.” Cautionary Statement Regarding Forward-Looking Statements This communication contains \"forward-looking statements\" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning potential product candidates, the potential of fibroblasts to transform wound care and FibroBiologics’ ability to make advanced treatments more accessible. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption \"Risk Factors\" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10...